Patents by Inventor Samuel DePrimo

Samuel DePrimo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
    Patent number: 11548941
    Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: January 10, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Julianty Angsana, Patrick Branigan, Samuel DePrimo, Susan Flavin, Shu Li, Xuejun Liu, Ernesto Munoz, Bruce Randazzo
  • SAFE AND EFFECTIVE METHOD OF TREATING PSORIASIS WITH ANTI-IL-23 SPECIFIC ANTIBODY
    Publication number: 20220289835
    Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.
    Type: Application
    Filed: May 2, 2022
    Publication date: September 15, 2022
    Inventors: Julianty Angsana, Patrick Branigan, Samuel DePrimo, Susan Flavin, Shu Li, Xeujun Liu, Ernesto Munoz, Bruce Randazzo
  • Safe and Effective Method of Treating Psoriasis with Anti-IL-23 Specific Antibody
    Publication number: 20200157209
    Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g.
    Type: Application
    Filed: November 19, 2019
    Publication date: May 21, 2020
    Inventors: Julianty Angsana, Patrick Branigan, Samuel DePrimo, Susan Flavin, Shu Li, Xuejun Liu, Ernesto Munoz, Bruce Randazzo
  • Use of MEK inhibitors in treating abnormal cell growth
    Publication number: 20060154990
    Abstract: This invention relates to use of the compound N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide for treating abnormal cell growth in mammals. In particular, the invention provides dosage regimes for administration of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to mammals suffering from cancer.
    Type: Application
    Filed: December 8, 2005
    Publication date: July 13, 2006
    Inventors: Mark Meyer, Samuel DePrimo, Judith Leopold, Seth Sadis, Matthew Spear, Weiwei Tan, Lloyd Whitfield
  • Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
    Publication number: 20040018528
    Abstract: The present invention describes novel methods that measure in a mammal the level of at least one biomarker, such as a protein and/or mRNA transcript. Based on the level of at least one biomarker in a mammal exposed to a test compound, compared to the level of the biomarker(s) in a mammal that has not been exposed to a test compound, the ability of the test compound to inhibit tyrosine kinase activity can be determined. The invention also relates to novel methods, wherein a change in the level of at least one biomarker in a mammal exposed to a compound, compared to the level of the biomarker(s) in a mammal that has not been exposed to the compound, indicates whether the mammal is being exposed to, or is experiencing or will experience a therapeutic or toxic effect in response to, a compound that inhibit tyrosine kinase activity.
    Type: Application
    Filed: May 19, 2003
    Publication date: January 29, 2004
    Applicant: Sugen, Inc.
    Inventors: Alyssa Morimoto, Samuel DePrimo, Anne-Marie O'Farrell, Beverly D. Smolich, William C. Manning, Sarah A. Walter, James W. Schilling, Julie Cherrington